2021
Genomic features of rapid versus late relapse in triple negative breast cancer
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorChemotherapy, AdjuvantDatasets as TopicDisease-Free SurvivalDNA Copy Number VariationsFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLogistic ModelsMastectomyMiddle AgedModels, GeneticMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRisk AssessmentTime FactorsTriple Negative Breast NeoplasmsConceptsLate relapseRapid relapseImmune signaturesBreast cancerAnti-tumor CD8 T cellsBackgroundTriple-negative breast cancerTriple-negative breast cancerCD8 T cellsTumor mutation burdenIndependent validation cohortNegative breast cancerFisher's exact testPearson's chi-squared testChi-squared testLogistic regression modelsLuminal signaturePrimary TNBCTNBC subsetImmune subsetsClinical featuresValidation cohortWhole-genome copy numberPrimary tumorM1 macrophagesT cells
2018
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study
Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research And Treatment 2018, 171: 325-334. PMID: 29789969, PMCID: PMC6076849, DOI: 10.1007/s10549-018-4828-5.Peer-Reviewed Original ResearchConceptsHormone receptor-positive advanced breast cancerAdvanced breast cancerIncidence of gradeAdverse eventsBreast cancerPhysical functionProgression-free survival benefitMultivariable logistic regression modelAddition of bevacizumabPhase III trialsPhysical function measuresAdverse event dataFunctional Assessment MeasureIncidence of toxicityFlight of stairsLogistic regression modelsHemorrhagic eventsIII trialsSurvival benefitMedian ageThrombosis eventsRisk factorsUnivariate analysisAssessment measuresBevacizumab
2014
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal Of Cancer 2014, 111: 1532-1541. PMID: 25101563, PMCID: PMC4200088, DOI: 10.1038/bjc.2014.444.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerChemotherapy responseClinical trialsProliferation signatureBreast cancerMultivariable logistic regression modelFuture clinical trialsBasal-like diseaseBasal-like subtypeIntrinsic molecular subtypesClinical pathological dataLogistic regression modelsBLBC subtypeIntrinsic subtypesSignificant interaction testMolecular subtypesCox modelIndependent cohortTNBC heterogeneityClinical implicationsSignificant associationBLBCChemotherapyPhenotypic subtypesLow expression
2013
Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study
Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study. Clinical Breast Cancer 2013, 13: 254-263. PMID: 23829891, PMCID: PMC4084778, DOI: 10.1016/j.clbc.2013.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingPractice Patterns, Physicians'PrognosisReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival RateTamoxifenYoung AdultConceptsTrastuzumab-based therapyFirst-line trastuzumab-based therapyAdvanced HER2-positive breast cancerHER2-positive breast cancerAdjuvant trastuzumabBreast cancerClinicopathological featuresClinical benefitC-statisticHuman epidermal growth factor-2-positive breast cancerTreatment durationPredictive valueHormone receptor-positive tumorsLong-term clinical benefitPrevious adjuvant trastuzumabTreatment duration groupsRetrospective cohort studyDisease-free intervalHormone receptor positivityReceptor-positive tumorsDuration of treatmentMagnitude of benefitLow predictive valueLogistic regression modelsDifferent logistic regression models
2010
Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104
Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. Journal Of Clinical Oncology 2010, 28: 2418-2422. PMID: 20368559, PMCID: PMC2881723, DOI: 10.1200/jco.2009.26.4671.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAge FactorsAgedAged, 80 and overAntimetabolites, AntineoplasticBreast NeoplasmsCanadaCapecitabineChemotherapy, AdjuvantDeoxycytidineDrug Administration ScheduleDrug MonitoringFemaleFluorouracilHumansKaplan-Meier EstimateLinear ModelsLogistic ModelsMastectomyMedication AdherenceMicro-Electrical-Mechanical SystemsNeoplasm StagingRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsEarly-stage breast cancerBreast cancerCALGB 49907Oral chemotherapyClinical trialsOlder womenPatients age 65 yearsOral adjuvant chemotherapyPill bottle openingsNode-negative diseaseHormone receptor statusRelapse-free survivalRandomized clinical trialsAge 65 yearsMulticenter clinical trialNumber of dosesPercent of participantsLogistic regression modelsAdjuvant chemotherapyProtocol therapyOral therapyStandard chemotherapyMedian ageReceptor statusPatient adherence
2009
Prevalence and Predictors of Distress in Young Women with Newly Diagnosed Early Stage Breast Cancer.
Ruddy K, Gelber S, Tamimi R, Mayer E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Prevalence and Predictors of Distress in Young Women with Newly Diagnosed Early Stage Breast Cancer. Cancer Research 2009, 69: 1067-1067. DOI: 10.1158/0008-5472.sabcs-09-1067.Peer-Reviewed Original ResearchStage breast cancerBreast cancerOverall distressYoung womenHADS scoresProspective multi-center cohort studyAdvanced-stage breast cancerMulti-center cohort studyEarly-stage breast cancerMultivariate logistic regression modelBaseline surveyOnly sociodemographic factorCentral pathology reviewEarly breast cancerMultivariate logistic regressionPercent of womenCourse of careMedical history itemsLogistic regression modelsBreast cancer diagnosisEligible womenCohort studyMedian agePathology reviewHospital AnxietyPathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study.
Collins L, Collins L, Gelber S, Gelber S, Ruddy K, Ruddy K, Tamimi R, Tamimi R, Come S, Come S, Marotti J, Marotti J, Schapira L, Schapira L, Kereakoglow S, Brachtel E, Brachtel E, Winer E, Winer E, Partridge A, Partridge A. Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study. Cancer Research 2009, 69: 6007-6007. DOI: 10.1158/0008-5472.sabcs-09-6007.Peer-Reviewed Original ResearchYoung Women's Breast Cancer StudyBreast Cancer StudyPoor prognostic featuresBasal-like carcinomasPathologic featuresBreast cancerYoung womenHER2 positivityPrognostic featuresTumor stageTumor necrosisER/PR negativityMulti-center prospective cohortInvasive breast cancerClinico-pathologic featuresHER2-positive tumorsCancer studiesHigh tumor gradeHigher tumor stageHigh-grade tumorsBasal-like phenotypeBiomarker expression patternsLogistic regression modelsPR negativityClinical characteristicsPersonalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making
Gold J, Najita J, Lester S, Richardson A, Morganstern D, Chen W, Partridge A, Krop I, Winer E, Burstein H. Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. Journal Of Clinical Oncology 2009, 27: 572-572. DOI: 10.1200/jco.2009.27.15_suppl.572.Peer-Reviewed Original ResearchEarly-stage breast cancerOncotype DX recurrence scoreRecurrence scoreDX recurrence scoreAdjuvant chemotherapyClinical factorsTumor gradeChemotherapy decisionsBreast cancerMultivariable logistic regression modelStandard clinicopathologic dataProgesterone receptor expressionReceipt of chemotherapyAdjuvant chemotherapy decisionsLow recurrence scoreHigh recurrence scoreStage breast cancerSingle academic institutionLikelihood of benefitStandard clinical factorsElectronic medical recordsLogistic regression modelsChemotherapy recommendationsMenopausal statusChemotherapy administration
2006
Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density
Abusief M, Missmer S, Ginsburg E, Weeks J, Winer E, Partridge A. Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density. Journal Of Clinical Oncology 2006, 24: 10506-10506. DOI: 10.1200/jco.2006.24.18_suppl.10506.Peer-Reviewed Original ResearchRisk of amenorrheaEarly breast cancerBreast cancerDDS therapyPremenopausal womenDana-Farber Cancer InstituteMultivariable logistic regression modelChemotherapy-related amenorrheaLikelihood of amenorrheaAddition of paclitaxelDose densityEffect of paclitaxelLogistic regression modelsAdjuvant chemotherapyTamoxifen useWomen's HospitalMultivariable modelMenstrual functioningAmenorrheaAverage ageCancer InstituteMenstrual dataPatientsAlcohol useTherapy